<DOC>
	<DOCNO>NCT01861002</DOCNO>
	<brief_summary>This Phase I study conditional cohort expansion phase evaluate feasibility , obtain preliminary efficacy data , pretreatment Azacytidine ( AZA ) 5 day follow fludarabine/cytarabine chemotherapy regimen pediatric acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) patient refractory primary treatment relapse .</brief_summary>
	<brief_title>A Phase I Study 5-Azacytidine Combination With Chemotherapy Children With Relapsed Refractory ALL AML</brief_title>
	<detailed_description>Growing evidence indicate aberrant DNA hypermethylation associate leukemia development , drug resistance , relapse . It show pretreating leukemia cell AZA decitabine could partially reverse aberrant DNA methylation , restore expression tumor suppressor gene important apoptosis , sensitize cell subsequent kill cytotoxic agent . Since cytarabine decitabine share mechanisms resistance , use AZA test novel epigenetic `` priming '' approach . This phase I clinical study expansion phase , use hypomethylating agent , 5-azacytidine ( AZA ) , sequential chemotherapy evaluate whether epigenetic `` priming '' reverse aberrant DNA methylation , overcome drug resistance , increase response relapsed/refractory AML . The chemotherapy regimen use study fludarabine cytarabine . This regimen substantial activity leukemia widely use treat pediatric patient relapsed/refractory AML ALL past several decades47 . In BFM relapse AML 2001/01 study , FLAG ( fludarabine , cytarabine G-CSF ) chemotherapy regimen show significant activity AML 4 year OS around 36 % .47 Since use G-CSF conjunction fludarabine/cytarabine n't improve overall survival patient randomize trial48 , fludarabine cytarabine use study decrease incidence leukocytosis related complication . This regimen similar chemotherapy regimen propose next relapsed AML trial within Children 's Oncology Group ( COG ) . If trial prof safe active , provide foundation smooth transition large statistically power nationwide phase II clinical trial COG .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must ≥ 1 ≤ 21 year age . Diagnosis 1 . Patients AML must ≥5 % blast ( morphology ) bone marrow . 2 . Patients ALL must M2 M3 marrow ( ≥5 % blast morphology ) . 3 . Patients may disease central nervous system ( CNS ) sit extramedullary disease . No cranial irradiation allow protocol therapy . 4 . Patients secondary AML eligible . 5 . Patients Down syndrome DNA fragility syndrome ( Fanconi anemia , Bloom syndrome ) exclude . Karnofsky &gt; 50 % patient &gt; 16 year age Lansky &gt; 50 % patient ≤ 16 year age . Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . Myelosuppressive chemotherapy eligibility criterion different phase I expansion phase 1 . Phase I Any patient AML 1st great relapse , OR Any patient ALL 2nd great relapse , OR Patients AML ALL fail go remission first great relapse , OR Patients AML ALL fail go remission original diagnosis two course induction attempt . 2 . Expansion phase restrict AML patient 3 . Cytoreduction hydroxyurea initiate continue 24 hour prior start azacytidine . It recommend use hydroxyurea patient significant leukocytosis ( WBC &gt; 50,000/L ) control blast count initiation systemic protocol therapy . 4 . Patients relapse receive cytotoxic therapy ( include AZA , decitabine , vorinostat ) At least 14 day must elapse since completion cytotoxic therapy . Hematopoietic stem cell transplant : Patients experience relapse stem cell transplant eligible , provide evidence acute chronic GraftversusHost Disease ( GVHD ) least 90 day posttransplant time enrollment . Hematopoietic growth factor : It must least 7 day since completion therapy filgrastim growth factor time enrollment . It must least 14 day since completion therapy pegfilgrastim ( Neulasta® ) . Biologic ( antineoplastic agent ) : At least 7 day last dose biologic agent . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study chair Monoclonal antibody : At least 3 halflives antibody must elapse last dose monoclonal antibody . ( i.e . Gemtuzumab = 36 day ) Immunotherapy : At least 42 day completion type immunotherapy , e.g . tumor vaccine . Radiation Therapy ( XRT ) : Craniospinal XRT prohibit protocol therapy . No washout period necessary radiation give nonCNS chloromas ; ≥ 90 day must elapse prior total body radiation craniospinal radiation . Renal hepatic function Patients must adequate renal hepatic function indicate follow laboratory value : Patient must calculate creatinine clearance radioisotope glomerular filtration rate ( GFR ) great equal 70ml/min/1.73m2 OR normal serum creatinine base age/gender . Direct bilirubin &lt; 1.5 x upper limit normal ( ULN ) age normal , AND alanine transaminase ( ALT ) &lt; 5 x ULN age . Adequate Cardiac Function Defined : Shortening fraction great equal 27 % echocardiogram , OR ejection fraction great equal 50 % radionuclide angiogram ( MUGA ) . Reproductive Function Female patient childbearing potential must negative urine serum pregnancy test confirm within 2 week prior enrollment . Female patient infant must agree breastfeed infant study . Male female patient childbearing potential must agree use effective method contraception approve investigator study minimum 6 month study treatment . Patients and/or parent legal guardian must capable understanding investigational nature , potential risk benefit study . All patient and/or parent legal guardian must sign write informed consent . Patients exclude know allergy drug use study . Patients exclude systemic fungal , bacterial , viral infection exhibit ongoing signs/symptoms related infection without improvement despite appropriate antibiotic treatment . The patient need pressor negative blood culture 48 hour . Patients exclude plan administer nonprotocol chemotherapy , radiation therapy , immunotherapy study period . Patients exclude significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance protocol treatment procedure , interfere consent , study participation , follow , interpretation study result . Patients Down syndrome DNA fragility syndrome ( Fanconi anemia , Bloom syndrome ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Relapse</keyword>
	<keyword>Lymphoblastic</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>Refractory</keyword>
	<keyword>Myelogenous</keyword>
	<keyword>Acute</keyword>
	<keyword>Childhood</keyword>
	<keyword>Pediatric</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>Methylation</keyword>
	<keyword>Epigenetic therapy</keyword>
</DOC>